Stocktoria
Neuphoria Therapeutics Inc. NEUP
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1999-12-21
Neuphoria Therapeutics Inc. financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $1.2M | $15.6M | — | — |
| R&D expense | — | $9.0M | $9.4M | $13.1M |
| Operating income | -$16.5M | -$1.1M | -$17.9M | -$22.0M |
| Income tax | -$139,173 | -$468,366 | -$87,320 | -$139,174 |
| Net income | -$13.5M | -$369,632 | -$15.5M | -$21.4M |
| EPS (diluted) | $-3.06 | $-0.23 | $-18.62 | $-0.02 |
| Operating cash flow | -$12.4M | $77,229 | -$14.7M | -$14.6M |
| Cash & equivalents | $19.9M | $14.2M | $12.6M | $12.1M |
| Total assets | $28.7M | $28.6M | $27.6M | $28.6M |
| Total liabilities | $4.1M | $9.6M | $10.2M | $6.6M |
| Shareholders' equity | $24.6M | $19.0M | $17.5M | $22.0M |
Growth · year-over-year · Revenue CAGR -92.5%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | -92.5% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.